학술논문

Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML
Document Type
Article
Source
In Blood Neoplasia June 2024 1(2)
Subject
Myeloid Neoplasia
Myelodysplastic Syndromes
Language
ISSN
2950-3280